In his study, Accurso assigned cystic fibrosis patients, all age or older, either to get inhaled denufosol or placebo three times a day for weeks. 모두 폐 기능 장애가 없거나 미미한 초기 단계의 질환을 앓고 있었습니다. For the next weeks, all participants got denufosol.